They would not announce any CR at an investment webinar. If anything, a CR is now a certainty given the results of the BIT trials being good but ot enough to attract a commercial deal.
On good and interesting thing raised was the emphasis on BIT chasing the general anti-viral drug sector - this could be BIT's big future.
SP at 4 cents makes exercising the options almost a no goer.
Ann: BIOTRON CLINICAL TRIAL RESULTS WEBINAR, page-87
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
